CompletedPhase 2NCT02048371
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- Robert Maki, MD, PhD, M.DUniversity of Pennsylvania
- Intervention
- Regorafenib(drug)
- Enrollment
- 131 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2014 – 2022
Study locations (18)
- City of Hope National Medical Center, Duarte, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Sarcoma Oncology Research Center, Santa Monica, California, United States
- Stanford University, Stanford, California, United States
- Mayo Clinic - Florida, Jacksonville, Florida, United States
- H. Lee Moffitt, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States
- Mayo Clinic - Minnesota, Rochester, Minnesota, United States
- Carolinas Healthcare System, Charlotte, North Carolina, United States
- Duke University, Durham, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Vanderbilt University, Nashville, Tennessee, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02048371 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGPHASE3NCT06127407Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenServier Bio-Innovation LLC
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO